A Model of the Cost-effectiveness of Intensity-modulated Radiotherapy in Comparison with Three-dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer

被引:21
作者
Hummel, S. R. [1 ]
Stevenson, M. D. [1 ]
Simpson, E. L. [1 ]
Staffurth, J. [2 ]
机构
[1] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield S1 4DA, S Yorkshire, England
[2] Cardiff Univ, Sch Med, Velindre Canc Ctr, Cardiff CF10 3AX, S Glam, Wales
关键词
Costs; cost-effectiveness; intensity modulation; local therapy; prostatic neoplasms; radiotherapy; RADIATION-THERAPY; ECONOMIC-MODEL; 70; GY; TOXICITY; MULTICENTER; SURVIVAL; TRIAL; IMRT;
D O I
10.1016/j.clon.2012.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To determine the cost-effectiveness of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for men with localised prostate cancer from a UK National Health Service perspective. Materials and methods: A discrete event simulation model was developed to simulate the progress of patients through advancing disease states until death from prostate cancer or other causes. Clinical effectiveness data for IMRT and 3DCRT were derived from a systematic review. Four scenarios were modelled based on different clinical studies. A probabilistic sensitivity analysis was undertaken and the incremental cost per quality adjusted life years (ICER) calculated. Results: In scenarios where estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER <20 pound 000). For scenarios where only a difference in late gastrointestinal toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was 35 pound 000, with a 20% probability that it is cost-effective at a maximum threshold of 20 pound 000 and a 48% probability at a threshold of 30 pound 000. Conclusion: If IMRT can be used to prolong survival, it is very cost-effective. Otherwise cost-effectiveness is uncertain. (C) 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E159 / E167
页数:9
相关论文
共 36 条
[1]  
[Anonymous], 2008, Guide to the methods of technology appraisal
[2]   Populating an Economic Model with Health State Utility Values: Moving toward Better Practice [J].
Ara, Roberta ;
Brazier, John E. .
VALUE IN HEALTH, 2010, 13 (05) :509-518
[3]   Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra [J].
Claxton, K ;
Sculpher, M ;
McCabe, C ;
Briggs, A ;
Akehurst, R ;
Buxton, M ;
Brazier, J ;
O'Hagan, T .
HEALTH ECONOMICS, 2005, 14 (04) :339-347
[4]  
Collins R, 2007, HEALTH TECHNOL ASSES, V11, P1
[5]  
CURTIS L., 2011, Unit Costs of Health and Social Care 2011
[6]   Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].
De Bono, Johann S. ;
Logothetis, Christopher J. ;
Molina, Arturo ;
Fizazi, Karim ;
North, Scott ;
Chu, Luis ;
Chi, Kim N. ;
Jones, Robert J. ;
Goodman, Oscar B., Jr. ;
Saad, Fred ;
Staffurth, John N. ;
Mainwaring, Paul ;
Harland, Stephen ;
Flaig, Thomas W. ;
Hutson, Thomas E. ;
Cheng, Tina ;
Patterson, Helen ;
Hainsworth, John D. ;
Ryan, Charles J. ;
Sternberg, Cora N. ;
Ellard, Susan L. ;
Flechon, Aude ;
Saleh, Mansoor ;
Scholz, Mark ;
Efstathiou, Eleni ;
Zivi, Andrea ;
Bianchini, Diletta ;
Loriot, Yohann ;
Chieffo, Nicole ;
Thian Kheoh ;
Haqq, Christopher M. ;
Scher, Howard I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005
[7]   Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial [J].
Dearnaley, David ;
Syndikus, Isabel ;
Sumo, Georges ;
Bidmead, Margaret ;
Bloomfield, David ;
Clark, Catharine ;
Gao, Annie ;
Hassan, Shama ;
Horwich, Alan ;
Huddart, Robert ;
Khoo, Vincent ;
Kirkbride, Peter ;
Mayles, Helen ;
Mayles, Philip ;
Naismith, Olivia ;
Parker, Chris ;
Patterson, Helen ;
Russell, Martin ;
Scrase, Christopher ;
South, Chris ;
Staffurth, John ;
Hall, Emma .
LANCET ONCOLOGY, 2012, 13 (01) :43-54
[8]   Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial [J].
Dearnaley, David P. ;
Sydes, Matthew R. ;
Graham, John D. ;
Aird, Edwin G. ;
Bottomley, David ;
Cowan, Richard A. ;
Huddart, Robert A. ;
Jose, Chakiath C. ;
Matthews, John H. L. ;
Millar, Jeremy ;
Moore, A. Rollo ;
Morgan, Rachel C. ;
Russell, J. Martin ;
Scrase, Christopher D. ;
Stephens, Richard J. ;
Syndikus, Isabel ;
Parmar, Mahesh K. B. .
LANCET ONCOLOGY, 2007, 8 (06) :475-487
[9]   Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial [J].
Dearnaley, DP ;
Khoo, VS ;
Norman, AR ;
Meyer, L ;
Nahum, A ;
Tait, D ;
Yarnold, J ;
Horwich, A .
LANCET, 1999, 353 (9149) :267-272
[10]   Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects [J].
Dearnaley, DP ;
Hall, E ;
Lawrence, D ;
Huddart, RA ;
Eeles, R ;
Nutting, CM ;
Gadd, J ;
Warrington, A ;
Bidmead, M ;
Horwich, A .
BRITISH JOURNAL OF CANCER, 2005, 92 (03) :488-498